ClinicalTrials.gg
CompletedNCT05274815WAYFINDERUpdated Dec 11, 2025Results posted

Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

A Phase 3 interventional study of Tezepelumab in Asthma, sponsored by AstraZeneca. Completed at 77 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
9th of 28
305 · median 121
Started
2022
with 3 others
Phase 3
16 of 28
4 open now
Registered
15th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 15th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.

Read the detailed description

This is a multicentre, single-arm, phase 3b study designed to evaluate efficacy and safety of reducing daily oral corticosteroid use after initiation of 210 mg dose of Tezepelumab administered subcutaneously in patients with severe asthma receiving high-dose inhaled corticosteroid plus long-acting β2 agonist and oral corticosteroids with or without additional asthma controller medications.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Severe Asthma
  • Oral Corticosteroids
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Age 18-80 years.
  • Documented physician diagnosed asthma requiring continuous treatment with high-dose ICS plus a LABA for at least 6 months prior to Visit 1. The ICS and LABA can be contained within a combination product or given by separate inhalers.
  • Documented long-term OCS therapy for asthma, equivalent to a daily dose of at least 5 mg and up to 40 mg of prednisone/prednisolone for at least 3 continuous months directly preceding Visit 1.
  • Participant should be on a stable maintenance OCS dose for at least 4 weeks prior to Visit 1.
  • Documented history of at least 1 asthma exacerbation event within 12 months prior to Visit 1.

Other inclusion criteria per protocol apply.

Main exclusion criteria:

  • Pulmonary disease or systemic diseases, other than asthma associated with elevated peripheral EOS counts.
  • Any disorder or major physical impairment that is not stable and could affect the safety of the participant throughout the study, influence the findings of the study or the interpretation, or impede the participant's ability to complete the entire duration of study.
  • History of cancer.
  • History of a infection requiring treatment with antibiotics, antiviral or additional medications finalised \< 2 weeks before Visit 1.
  • A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
  • Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes.
  • History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
  • Tuberculosis requiring treatment within the 12 months prior to Visit 1.
  • History of known immunodeficiency disorder including a positive test at Visit 1.
  • Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures requiring general anaesthesia or inpatient status for > 1 day during the conduct of the study.
  • Coexistent inflammatory conditions for which long-term OCS doses are part of their maintenance treatment.
  • Receipt of any marketed or biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1. Participants enrolled in current or previous tezepelumab studies will not be included.
  • Concurrent enrolment in another clinical study involving an IP.
  • Treatment with systemic /immunomodulating drugs, except for OCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
  • History of anaphylaxis or documented immune complex disease (Type III reactions) following any biologic therapy.
  • Positive surface antigen, or virus antibody serology at screening, or a positive medical history for hepatitis B or C.
  • Pregnant, breastfeeding, or lactating women.

Other exclusion criteria per protocol apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab subcutaneous injection

    Biological: Tezepelumab

Interventions

  • BiologicalTezepelumab

    Tezepelumab subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Proportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52

    The proportion (expressed as a percentage) of participants who discontinued OCS without loss of asthma control is presented. Loss of asthma control was defined as asthma worsening or exacerbation. Asthma worsening was defined by an increase of Asthma Control Questionnaire 6 (ACQ-6) score ≥0.5 from baseline. Asthma exacerbation was defined by worsening of asthma symptoms that led to temporary bolus/burst of systemic corticosteroids (SCS; or a temporary increase in stable OCS background dose) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids being considered equivalent to a 3-day bolus/burst of SCS), and/or an emergency room (ER) or urgent care visit requiring SCS, and/or inpatient hospitalisation, both due to asthma.

    Time frame: Week 28 and Week 52

  2. Proportion of the Participants Who Reduced Daily Prescribed Maintenance OCS Dose to ≤5 mg/Day Without Loss of Asthma Control at Week 28 and Week 52

    The proportion (expressed as a percentage) of the participants who reduced daily prescribed maintenance OCS dose to ≤5 mg/day without loss of asthma control at Week 28 and Week 52 is presented.

    Time frame: Week 28 and Week 52

Secondary outcomes

  1. Annual Asthma Exacerbation Rate (AAER) Over Week 28 and Over Week 52

    The AAER over Week 28 and over Week 52 is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).

    Time frame: Week 28 and Week 52

  2. Rate of Asthma Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks

    The AAER for exacerbations associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).

    Time frame: Week 28 and Week 52

  3. Rate of Asthma Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks

    The AAER for exacerbations associated with hospitalisation over 28 weeks and over 52 weeks are presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).

    Time frame: Week 28 and Week 52

  4. Proportion of the Participants Who Did Not Experience an Exacerbation Over 28 Weeks and Over 52 Weeks

    The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation over 28 weeks and over 52 weeks is presented.

    Time frame: Week 28 and Week 52

  5. Proportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks

    The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented.

    Time frame: Week 28 and Week 52

  6. Proportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks

    The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation over 28 weeks and over 52 weeks is presented.

    Time frame: Week 28 and Week 52

  7. Proportion of the Participants With ≥50% Reduction From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52

    The proportion (expressed as a percentage) of participants with ≥50% reduction from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of investigational product (IP). The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

    Time frame: Week 28 and Week 52

  8. Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 and Week 52

    The categorised percent reduction from baseline in the daily maintenance OCS dose (categories: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, no change or any increase) at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

    Time frame: Week 28 and Week 52

  9. Absolute Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52

    The absolute change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

    Time frame: Week 28 and Week 52

  10. Percent Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52

    The percent change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

    Time frame: Week 28 and Week 52

  11. Change From Baseline in Post-bronchodilator FEV1 at Week 28 and Week 52

    The change from baseline in post-bronchodilator FEV1 at Week 28 and Week 52 is presented. Baseline was defined as the last measurement at or prior first dose of IP. FEV1 = forced expiratory volume in 1 second

    Time frame: Week 28 and Week 52

  12. Change From Baseline in ACQ-6 at Week 28 and Week 52

    The Asthma Control Questionnaire 6 (ACQ-6) is a 6-item questionnaire which includes the following questions: 1) Awakening at night by symptoms, 2) Limitations of normal daily activities, 3) Waking in the morning with symptoms, 4) Dyspnoea, 5) Wheeze, and 6) Daily rescue medication. Questions were scored from 0 (totally controlled) to 6 (severely uncontrolled) and the ACQ-6 score was computed as the unweighted mean of the responses to the 6 questions. Higher scores indicate poorer outcomes. The change from baseline in ACQ-6 at Week 28 and Week 52 is presented.

    Time frame: Week 28 and Week 52

  13. Change From Baseline in Standardised AQLQ(s)+12 Total Score at Week 28 and Week 52

    The Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ\[S\]+12) is a questionnaire that measures the health-related quality of life experienced by asthma participants. Questions were scored from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. Higher scores indicate better outcomes. The change from baseline in standardised AQLQ(S)+12 total score at Week 28 and Week 52 is presented.

    Time frame: Week 28 and Week 52

  14. Change From Baseline in SGRQ Total Score at Week 28 and Week 52

    The St. George's Respiratory Questionnaire (SGRQ) is a 50-item instrument developed to measure the health status of participants with airway obstruction diseases. The total score indicates the impact of disease on overall health status. The total score ranges for the SGRQ are 0-100, with higher scores indicating worse health status. The change from baseline in SGRQ total score at Week 28 and Week 52 is presented.

    Time frame: Week 28 and Week 52

07

Results

Posted Dec 11, 2025

Participant flow

A total of 305 participants were enrolled from 68 study sites across 11 countries, including sites in Argentina, Belgium, Bulgaria, France, Germany, Latvia, Mexico, Poland, Spain, UK, and USA.

Participant flow — Overall Study
MilestoneTezepelumab
Started298
Completed273
Not completed25
Withdrew: Adverse event1
Withdrew: Death2
Withdrew: Lost to follow-up4
Withdrew: Withdrawn from study due to investigator's decision1
Withdrew: Withdrawn from study due to participant's decision to withdraw1
Withdrew: Withdrawn from study due to severe non-compliance with the protocol1
Withdrew: Withdrawn from study due to subject decision1
Withdrew: Withdrawn due to participant's decision not to continue for personal and family reasons1
Withdrew: Withdrawn from study due to the participant stopped visit; agreed to a telephone contact at week 521
Withdrew: Withdrawn from study due to randomization into closed cohort by mistake1
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryProportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52

The proportion (expressed as a percentage) of participants who discontinued OCS without loss of asthma control is presented. Loss of asthma control was defined as asthma worsening or exacerbation. Asthma worsening was defined by an increase of Asthma Control Questionnaire 6 (ACQ-6) score ≥0.5 from baseline. Asthma exacerbation was defined by worsening of asthma symptoms that led to temporary bolus/burst of systemic corticosteroids (SCS; or a temporary increase in stable OCS background dose) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids being considered equivalent to a 3-day bolus/burst of SCS), and/or an emergency room (ER) or urgent care visit requiring SCS, and/or inpatient hospitalisation, both due to asthma.

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage of participants
Proportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52
Percentage of participantsTezepelumab
Week 2832.2 (26.9 to 37.8)
Week 5250.3 (44.5 to 56.2)
PrimaryProportion of the Participants Who Reduced Daily Prescribed Maintenance OCS Dose to ≤5 mg/Day Without Loss of Asthma Control at Week 28 and Week 52

The proportion (expressed as a percentage) of the participants who reduced daily prescribed maintenance OCS dose to ≤5 mg/day without loss of asthma control at Week 28 and Week 52 is presented.

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage of participants
Proportion of the Participants Who Reduced Daily Prescribed Maintenance OCS Dose to ≤5 mg/Day Without Loss of Asthma Control at Week 28 and Week 52
Percentage of participantsTezepelumab
Week 2888.9 (84.8 to 92.3)
Week 5289.9 (85.9 to 93.1)
SecondaryAnnual Asthma Exacerbation Rate (AAER) Over Week 28 and Over Week 52

The AAER over Week 28 and over Week 52 is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).

Time frame:
Week 28 and Week 52
Reported as:
Number · exacerbations/year
Annual Asthma Exacerbation Rate (AAER) Over Week 28 and Over Week 52
exacerbations/yearTezepelumab
Week 280.66
Week 520.57
SecondaryRate of Asthma Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks

The AAER for exacerbations associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).

Time frame:
Week 28 and Week 52
Reported as:
Number · exacerbations/year
Rate of Asthma Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks
exacerbations/yearTezepelumab
Week 280.13
Week 520.11
SecondaryRate of Asthma Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks

The AAER for exacerbations associated with hospitalisation over 28 weeks and over 52 weeks are presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).

Time frame:
Week 28 and Week 52
Reported as:
Number · exacerbations/year
Rate of Asthma Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks
exacerbations/yearTezepelumab
Week 280.06
Week 520.05
SecondaryProportion of the Participants Who Did Not Experience an Exacerbation Over 28 Weeks and Over 52 Weeks

The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation over 28 weeks and over 52 weeks is presented.

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage of participants
Proportion of the Participants Who Did Not Experience an Exacerbation Over 28 Weeks and Over 52 Weeks
Percentage of participantsTezepelumab
Week 2876.0 (70.68 to 80.85)
Week 5266.9 (61.01 to 72.44)
SecondaryProportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks

The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented.

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage of participants
Proportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks
Percentage of participantsTezepelumab
Week 2895.5 (92.40 to 97.57)
Week 5292.7 (88.99 to 95.50)
SecondaryProportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks

The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation over 28 weeks and over 52 weeks is presented.

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage
Proportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks
PercentageTezepelumab
Week 2897.9 (95.52 to 99.23)
Week 5296.0 (92.96 to 97.99)
SecondaryProportion of the Participants With ≥50% Reduction From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52

The proportion (expressed as a percentage) of participants with ≥50% reduction from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of investigational product (IP). The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage of participants
Proportion of the Participants With ≥50% Reduction From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52
Percentage of participantsTezepelumab
Week 2876.8 (71.6 to 81.5)
Week 5281.9 (77.0 to 86.1)
SecondaryCategorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 and Week 52

The categorised percent reduction from baseline in the daily maintenance OCS dose (categories: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, no change or any increase) at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

Time frame:
Week 28 and Week 52
Reported as:
Number · Percentage of participants
Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 and Week 52
Percentage of participantsTezepelumab (Week 28)
Week 28: ≥90% to ≤100% reduction35.2 (29.8 to 41.0)
Week 28: ≥75% to <90% reduction14.1 (10.4 to 18.6)
Week 28: ≥50% to <75% reduction27.5 (22.5 to 33.0)
Week 28: >0% to <50% reduction8.1 (5.2 to 11.7)
Week 28: No change or any increase15.1 (11.2 to 19.7)
Week 52: ≥90% to ≤100% reduction52.0 (46.2 to 57.8)
Week 52: ≥75% to <90% reduction9.1 (6.1 to 12.9)
Week 52: ≥50% to <75% reduction20.8 (16.3 to 25.9)
Week 52: >0% to <50% reduction4.0 (2.1 to 6.9)
Week 52: No change or any increase14.1 (10.4 to 18.6)
SecondaryAbsolute Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52

The absolute change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

Time frame:
Week 28 and Week 52
Reported as:
Mean · mg
Absolute Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52
mgTezepelumab
Week 28-6.951 ± 5.596
Week 52-7.704 ± 6.294
SecondaryPercent Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52

The percent change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).

Time frame:
Week 28 and Week 52
Reported as:
Mean · Percentage change
Percent Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52
Percentage changeTezepelumab
Week 28-61.919 ± 41.773
Week 52-69.844 ± 43.666
SecondaryChange From Baseline in Post-bronchodilator FEV1 at Week 28 and Week 52

The change from baseline in post-bronchodilator FEV1 at Week 28 and Week 52 is presented. Baseline was defined as the last measurement at or prior first dose of IP. FEV1 = forced expiratory volume in 1 second

Time frame:
Week 28 and Week 52
Reported as:
Mean · liter (L)
Change From Baseline in Post-bronchodilator FEV1 at Week 28 and Week 52
liter (L)Tezepelumab
Week 280.0885 ± 0.3405
Week 520.0737 ± 0.3559
SecondaryChange From Baseline in ACQ-6 at Week 28 and Week 52

The Asthma Control Questionnaire 6 (ACQ-6) is a 6-item questionnaire which includes the following questions: 1) Awakening at night by symptoms, 2) Limitations of normal daily activities, 3) Waking in the morning with symptoms, 4) Dyspnoea, 5) Wheeze, and 6) Daily rescue medication. Questions were scored from 0 (totally controlled) to 6 (severely uncontrolled) and the ACQ-6 score was computed as the unweighted mean of the responses to the 6 questions. Higher scores indicate poorer outcomes. The change from baseline in ACQ-6 at Week 28 and Week 52 is presented.

Time frame:
Week 28 and Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in ACQ-6 at Week 28 and Week 52
Score on a scaleTezepelumab
Week 28-1.12 ± 1.00
Week 52-1.20 ± 1.09
SecondaryChange From Baseline in Standardised AQLQ(s)+12 Total Score at Week 28 and Week 52

The Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ\[S\]+12) is a questionnaire that measures the health-related quality of life experienced by asthma participants. Questions were scored from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. Higher scores indicate better outcomes. The change from baseline in standardised AQLQ(S)+12 total score at Week 28 and Week 52 is presented.

Time frame:
Week 28 and Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Standardised AQLQ(s)+12 Total Score at Week 28 and Week 52
Score on a scaleTezepelumab
Week 281.1455 ± 1.0419
Week 521.1932 ± 1.1551
SecondaryChange From Baseline in SGRQ Total Score at Week 28 and Week 52

The St. George's Respiratory Questionnaire (SGRQ) is a 50-item instrument developed to measure the health status of participants with airway obstruction diseases. The total score indicates the impact of disease on overall health status. The total score ranges for the SGRQ are 0-100, with higher scores indicating worse health status. The change from baseline in SGRQ total score at Week 28 and Week 52 is presented.

Time frame:
Week 28 and Week 52
Reported as:
Mean · score
Change From Baseline in SGRQ Total Score at Week 28 and Week 52
scoreTezepelumab
Week 28-16.2919 ± 18.1489
Week 52-16.6593 ± 18.7749

Adverse events

Collected over From the date of first dose of IP until study completion or withdrawal date, up to 64 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab2/298 (0.7%)28/298 (9.4%)4/298 (1.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTezepelumab
AsthmaRespiratory, thoracic and mediastinal disorders13/298
PneumoniaInfections and infestations3/298
Angina pectorisCardiac disorders2/298
Atrial fibrillationCardiac disorders2/298
Adrenocortical insufficiency acuteEndocrine disorders1/298
DysphagiaGastrointestinal disorders1/298
GastritisGastrointestinal disorders1/298
Pancreatitis acuteGastrointestinal disorders1/298
VomitingGastrointestinal disorders1/298
Bile duct stoneHepatobiliary disorders1/298
Most frequent other events
Most frequent other events
EventTezepelumab
Adrenal insufficiencyEndocrine disorders1/298
InsomniaPsychiatric disorders1/298
Atrial fibrillationCardiac disorders1/298
TinnitusEar and labyrinth disorders1/298

Baseline characteristics

Full Analysis Set: included all enrolled participants who received at least one dose of tezepelumab, irrespective of their protocol adherence and continued participation in the study.

Age, Continuous
Age, Continuous(Years)Tezepelumab
Mean54.4 ± 12.0
Age, Customized
Age, Customized(Participants)Tezepelumab
>=18 to <65 years231
>=65 years67
Sex: Female, Male
Sex: Female, Male(Participants)Tezepelumab
Female206
Male92
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab
Hispanic or Latino123
Not Hispanic or Latino157
Missing18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab
Black or African American2
American Indian or Alaska Native5
White258
Other15
Not reported18
Region of Enrollment
Region of Enrollment(Participants)Tezepelumab
Argentina80
Belgium13
Bulgaria36
France18
Germany22
Latvia16
Mexico41
Poland40
Spain8
United States12
United Kingdom12
08

Study locations

77 sites
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Loxahatchee Groves, Florida 33470, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Toms River, New Jersey 08755, United States
  • Research Site
    The Bronx, New York 10467, United States
  • Research Site
    DuBois, Pennsylvania 15801, United States
  • Research Site
    Buenos Aires, C1121ABE, Argentina
  • Research Site
    CABA, 1426, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    Mendoza, M5500GHB, Argentina
  • Research Site
    Monte Grande, 1842, Argentina
  • Research Site
    Pilar, 1629, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    Ranelagh, 1886, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Brussels (Woluwé-St-Lambert), 1200, Belgium
  • Research Site
    Erpent, 5101, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Haskovo, 6305, Bulgaria
  • Research Site
    Razgrad, 7200, Bulgaria
  • Research Site
    Sofia, 1142, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 5000, Bulgaria
  • Research Site
    Velika Tarnovo, 5250, Bulgaria
  • Research Site
    Antony, 92160, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Lyon, 69004, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Montpellier, France
  • Research Site
    Nantes, 44000, France
  • Research Site
    Nice, 06000, France
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Darmstadt, 64283, Germany
  • Research Site
    Fürstenwalde, 15517, Germany
  • Research Site
    Mainz, 55128, Germany
  • Research Site
    Reinfeld (Holstein), 23858, Germany
  • Research Site
    Daugavpils, LV-5410, Latvia
  • Research Site
    Daugavpils, LV-5417, Latvia
  • Research Site
    Jūrmala, LV-2015, Latvia
  • Research Site
    Riga, LV-1011, Latvia
  • Research Site
    Riga, LV1002, Latvia
  • Research Site
    Riga, LV1010, Latvia
  • Research Site
    Valmiera, LV-4201, Latvia
  • Research Site
    Chihuahua City, 31000, Mexico
  • Research Site
    Chihuahua City, 31200, Mexico
  • Research Site
    Guadalajara, 44100, Mexico
  • Research Site
    Monterrey, 64360, Mexico
  • Research Site
    Bychawa, 23100, Poland
  • Research Site
    Chmielnik, 26-020, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Krakow, 31-011, Poland
  • Research Site
    Lodz, 92-213, Poland
  • Research Site
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Research Site
    Sosnowiec, 41-200, Poland
  • Research Site
    Wroclaw, 50-044, Poland
  • Research Site
    Wroclaw, 53-301, Poland
  • Research Site
    Wroclaw, 54-239, Poland
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Santa Cruz de Tenerife, 38010, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Belfast, BT97AB, United Kingdom
  • Research Site
    Bradford, BD9 6RJ, United Kingdom
  • Research Site
    LE3 9QP, United Kingdom
  • Research Site
    London, SE1 7EH, United Kingdom
  • Research Site
    London, SW3 6HP, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Portsmouth, PO6 3LY, United Kingdom
09

References and documents

Publications

  • Jackson DJ, Lugogo NL, Gurnell M, Heaney LG, Korn S, Brusselle G, Chanez P, Del Olmo R, Llanos JP, Keeling N, Salapa K, Cook B, Parulekar AD, Kostikas K, Fogel R, Martin N, Chandarana SN. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. Lancet Respir Med. 2026 Feb;14(2):129-140. doi: 10.1016/S2213-2600(25)00359-5. Epub 2025 Nov 26. PubMed 41317738 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of the timelines, please rerefer to the disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2024, 27 months.

Results were first posted in Dec 2025, 1 year 3 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Mar 10, 2022
StartActual
May 17, 2022
Primary completionActual
Sep 9, 2024
CompletionActual
Sep 9, 2024
Results first posted
Dec 11, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05274815
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 10, 2022
Start date
May 17, 2022
Primary completion
Sep 9, 2024
Completion
Sep 9, 2024
Results posted
Dec 11, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion